 | • レポートコード：MRC2Q12-18883 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、生物学的ワクチン補助剤のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 生物学的ワクチン補助剤のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生物学的ワクチン補助剤の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生物学的ワクチン補助剤のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの生物学的ワクチン補助剤の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の生物学的ワクチン補助剤の売上および2028年までの予測に焦点を当てています。 生物学的ワクチン補助剤のグローバル主要企業には、GSK、Dynavax Technologies、Novavax、Agenus、Croda International、Seppic、OZ Biosciences、Phibro Animal Health Corporation、Associated British Foods、InvivoGen、Merck KGaA、CSL Limited、Vertellus、Allergy Therapeutics、Riboxx GmbH、CaPtivatϵ Pharmaceuticals、EuBiologics、Pacific GeneTech、Hawaii Biotech、Vaxine Pty Ltd.、Creative Diagnostics、LiteVax BV、Mukta Industries、Oncovir、TiterMax USAなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 生物学的ワクチン補助剤市場は、タイプとアプリケーションによって区分されます。世界の生物学的ワクチン補助剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 アルミニウム補助剤、乳剤補助剤、その他 【アプリケーション別セグメント】 人間用ワクチン、動物用ワクチン 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 生物学的ワクチン補助剤製品概要 - タイプ別市場（アルミニウム補助剤、乳剤補助剤、その他） - アプリケーション別市場（人間用ワクチン、動物用ワクチン） - 調査の目的 ・エグゼクティブサマリー - 世界の生物学的ワクチン補助剤販売量予測2017-2028 - 世界の生物学的ワクチン補助剤売上予測2017-2028 - 生物学的ワクチン補助剤の地域別販売量 - 生物学的ワクチン補助剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別生物学的ワクチン補助剤販売量 - 主要メーカー別生物学的ワクチン補助剤売上 - 主要メーカー別生物学的ワクチン補助剤価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（アルミニウム補助剤、乳剤補助剤、その他） - 生物学的ワクチン補助剤のタイプ別販売量 - 生物学的ワクチン補助剤のタイプ別売上 - 生物学的ワクチン補助剤のタイプ別価格 ・アプリケーション別市場規模（人間用ワクチン、動物用ワクチン） - 生物学的ワクチン補助剤のアプリケーション別販売量 - 生物学的ワクチン補助剤のアプリケーション別売上 - 生物学的ワクチン補助剤のアプリケーション別価格 ・北米市場 - 北米の生物学的ワクチン補助剤市場規模（タイプ別、アプリケーション別） - 主要国別の生物学的ワクチン補助剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの生物学的ワクチン補助剤市場規模（タイプ別、アプリケーション別） - 主要国別の生物学的ワクチン補助剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の生物学的ワクチン補助剤市場規模（タイプ別、アプリケーション別） - 主要国別の生物学的ワクチン補助剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の生物学的ワクチン補助剤市場規模（タイプ別、アプリケーション別） - 主要国別の生物学的ワクチン補助剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの生物学的ワクチン補助剤市場規模（タイプ別、アプリケーション別） - 主要国別の生物学的ワクチン補助剤市場規模（トルコ、サウジアラビア） ・企業情報 GSK、Dynavax Technologies、Novavax、Agenus、Croda International、Seppic、OZ Biosciences、Phibro Animal Health Corporation、Associated British Foods、InvivoGen、Merck KGaA、CSL Limited、Vertellus、Allergy Therapeutics、Riboxx GmbH、CaPtivatϵ Pharmaceuticals、EuBiologics、Pacific GeneTech、Hawaii Biotech、Vaxine Pty Ltd.、Creative Diagnostics、LiteVax BV、Mukta Industries、Oncovir、TiterMax USA ・産業チェーン及び販売チャネル分析 - 生物学的ワクチン補助剤の産業チェーン分析 - 生物学的ワクチン補助剤の原材料 - 生物学的ワクチン補助剤の生産プロセス - 生物学的ワクチン補助剤の販売及びマーケティング - 生物学的ワクチン補助剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 生物学的ワクチン補助剤の産業動向 - 生物学的ワクチン補助剤のマーケットドライバー - 生物学的ワクチン補助剤の課題 - 生物学的ワクチン補助剤の阻害要因 ・主な調査結果 |
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Biological Vaccines Adjuvants is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Biological Vaccines Adjuvants is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Biological Vaccines Adjuvants is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Biological Vaccines Adjuvants include GSK, Dynavax Technologies, Novavax, Agenus, Croda International, Seppic, OZ Biosciences, Phibro Animal Health Corporation and Associated British Foods, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Biological Vaccines Adjuvants manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Biological Vaccines Adjuvants market. Further, it explains the major drivers and regional dynamics of the global Biological Vaccines Adjuvants market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
GSK
Dynavax Technologies
Novavax
Agenus
Croda International
Seppic
OZ Biosciences
Phibro Animal Health Corporation
Associated British Foods
InvivoGen
Merck KGaA
CSL Limited
Vertellus
Allergy Therapeutics
Riboxx GmbH
CaPtivatϵ Pharmaceuticals
EuBiologics
Pacific GeneTech
Hawaii Biotech
Vaxine Pty Ltd.
Creative Diagnostics
LiteVax BV
Mukta Industries
Oncovir
TiterMax USA
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Biological Vaccines Adjuvants Segment by Type
Aluminum Adjuvant
Emulsions Adjuvant
Others
Biological Vaccines Adjuvants Segment by Application
Human Vaccine
Veterinary Vaccine
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biological Vaccines Adjuvants market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Biological Vaccines Adjuvants, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Biological Vaccines Adjuvants, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Biological Vaccines Adjuvants, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biological Vaccines Adjuvants sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Biological Vaccines Adjuvants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Biological Vaccines Adjuvants sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Dynavax Technologies, Novavax, Agenus, Croda International, Seppic, OZ Biosciences, Phibro Animal Health Corporation and Associated British Foods, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Biological Vaccines Adjuvants in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Biological Vaccines Adjuvants manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biological Vaccines Adjuvants sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Biological Vaccines Adjuvants Product Introduction
1.2 Market by Type
1.2.1 Global Biological Vaccines Adjuvants Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Aluminum Adjuvant
1.2.3 Emulsions Adjuvant
1.2.4 Others
1.3 Market by Application
1.3.1 Global Biological Vaccines Adjuvants Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Human Vaccine
1.3.3 Veterinary Vaccine
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Biological Vaccines Adjuvants Sales Estimates and Forecasts 2017-2028
2.2 Global Biological Vaccines Adjuvants Revenue Estimates and Forecasts 2017-2028
2.3 Global Biological Vaccines Adjuvants Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Biological Vaccines Adjuvants Sales by Region
2.4.1 Global Biological Vaccines Adjuvants Sales by Region (2017-2022)
2.4.2 Global Sales Biological Vaccines Adjuvants by Region (2023-2028)
2.5 Global Biological Vaccines Adjuvants Revenue by Region
2.5.1 Global Biological Vaccines Adjuvants Revenue by Region (2017-2022)
2.5.2 Global Biological Vaccines Adjuvants Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Biological Vaccines Adjuvants Sales by Manufacturers
3.1.1 Global Top Biological Vaccines Adjuvants Manufacturers by Sales (2017-2022)
3.1.2 Global Biological Vaccines Adjuvants Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biological Vaccines Adjuvants in 2021
3.2 Global Biological Vaccines Adjuvants Revenue by Manufacturers
3.2.1 Global Biological Vaccines Adjuvants Revenue by Manufacturers (2017-2022)
3.2.2 Global Biological Vaccines Adjuvants Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Biological Vaccines Adjuvants Revenue in 2021
3.3 Global Biological Vaccines Adjuvants Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Biological Vaccines Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Biological Vaccines Adjuvants Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Biological Vaccines Adjuvants Sales by Type
4.1.1 Global Biological Vaccines Adjuvants Historical Sales by Type (2017-2022)
4.1.2 Global Biological Vaccines Adjuvants Forecasted Sales by Type (2023-2028)
4.1.3 Global Biological Vaccines Adjuvants Sales Market Share by Type (2017-2028)
4.2 Global Biological Vaccines Adjuvants Revenue by Type
4.2.1 Global Biological Vaccines Adjuvants Historical Revenue by Type (2017-2022)
4.2.2 Global Biological Vaccines Adjuvants Forecasted Revenue by Type (2023-2028)
4.2.3 Global Biological Vaccines Adjuvants Revenue Market Share by Type (2017-2028)
4.3 Global Biological Vaccines Adjuvants Price by Type
4.3.1 Global Biological Vaccines Adjuvants Price by Type (2017-2022)
4.3.2 Global Biological Vaccines Adjuvants Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Biological Vaccines Adjuvants Sales by Application
5.1.1 Global Biological Vaccines Adjuvants Historical Sales by Application (2017-2022)
5.1.2 Global Biological Vaccines Adjuvants Forecasted Sales by Application (2023-2028)
5.1.3 Global Biological Vaccines Adjuvants Sales Market Share by Application (2017-2028)
5.2 Global Biological Vaccines Adjuvants Revenue by Application
5.2.1 Global Biological Vaccines Adjuvants Historical Revenue by Application (2017-2022)
5.2.2 Global Biological Vaccines Adjuvants Forecasted Revenue by Application (2023-2028)
5.2.3 Global Biological Vaccines Adjuvants Revenue Market Share by Application (2017-2028)
5.3 Global Biological Vaccines Adjuvants Price by Application
5.3.1 Global Biological Vaccines Adjuvants Price by Application (2017-2022)
5.3.2 Global Biological Vaccines Adjuvants Price Forecast by Application (2023-2028)
6 North America
6.1 North America Biological Vaccines Adjuvants Market Size by Type
6.1.1 North America Biological Vaccines Adjuvants Sales by Type (2017-2028)
6.1.2 North America Biological Vaccines Adjuvants Revenue by Type (2017-2028)
6.2 North America Biological Vaccines Adjuvants Market Size by Application
6.2.1 North America Biological Vaccines Adjuvants Sales by Application (2017-2028)
6.2.2 North America Biological Vaccines Adjuvants Revenue by Application (2017-2028)
6.3 North America Biological Vaccines Adjuvants Market Size by Country
6.3.1 North America Biological Vaccines Adjuvants Sales by Country (2017-2028)
6.3.2 North America Biological Vaccines Adjuvants Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Biological Vaccines Adjuvants Market Size by Type
7.1.1 Europe Biological Vaccines Adjuvants Sales by Type (2017-2028)
7.1.2 Europe Biological Vaccines Adjuvants Revenue by Type (2017-2028)
7.2 Europe Biological Vaccines Adjuvants Market Size by Application
7.2.1 Europe Biological Vaccines Adjuvants Sales by Application (2017-2028)
7.2.2 Europe Biological Vaccines Adjuvants Revenue by Application (2017-2028)
7.3 Europe Biological Vaccines Adjuvants Market Size by Country
7.3.1 Europe Biological Vaccines Adjuvants Sales by Country (2017-2028)
7.3.2 Europe Biological Vaccines Adjuvants Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Biological Vaccines Adjuvants Market Size by Type
8.1.1 Asia Pacific Biological Vaccines Adjuvants Sales by Type (2017-2028)
8.1.2 Asia Pacific Biological Vaccines Adjuvants Revenue by Type (2017-2028)
8.2 Asia Pacific Biological Vaccines Adjuvants Market Size by Application
8.2.1 Asia Pacific Biological Vaccines Adjuvants Sales by Application (2017-2028)
8.2.2 Asia Pacific Biological Vaccines Adjuvants Revenue by Application (2017-2028)
8.3 Asia Pacific Biological Vaccines Adjuvants Market Size by Region
8.3.1 Asia Pacific Biological Vaccines Adjuvants Sales by Region (2017-2028)
8.3.2 Asia Pacific Biological Vaccines Adjuvants Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Biological Vaccines Adjuvants Market Size by Type
9.1.1 Latin America Biological Vaccines Adjuvants Sales by Type (2017-2028)
9.1.2 Latin America Biological Vaccines Adjuvants Revenue by Type (2017-2028)
9.2 Latin America Biological Vaccines Adjuvants Market Size by Application
9.2.1 Latin America Biological Vaccines Adjuvants Sales by Application (2017-2028)
9.2.2 Latin America Biological Vaccines Adjuvants Revenue by Application (2017-2028)
9.3 Latin America Biological Vaccines Adjuvants Market Size by Country
9.3.1 Latin America Biological Vaccines Adjuvants Sales by Country (2017-2028)
9.3.2 Latin America Biological Vaccines Adjuvants Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Biological Vaccines Adjuvants Market Size by Type
10.1.1 Middle East and Africa Biological Vaccines Adjuvants Sales by Type (2017-2028)
10.1.2 Middle East and Africa Biological Vaccines Adjuvants Revenue by Type (2017-2028)
10.2 Middle East and Africa Biological Vaccines Adjuvants Market Size by Application
10.2.1 Middle East and Africa Biological Vaccines Adjuvants Sales by Application (2017-2028)
10.2.2 Middle East and Africa Biological Vaccines Adjuvants Revenue by Application (2017-2028)
10.3 Middle East and Africa Biological Vaccines Adjuvants Market Size by Country
10.3.1 Middle East and Africa Biological Vaccines Adjuvants Sales by Country (2017-2028)
10.3.2 Middle East and Africa Biological Vaccines Adjuvants Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Overview
11.1.3 GSK Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 GSK Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GSK Recent Developments
11.2 Dynavax Technologies
11.2.1 Dynavax Technologies Corporation Information
11.2.2 Dynavax Technologies Overview
11.2.3 Dynavax Technologies Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Dynavax Technologies Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Dynavax Technologies Recent Developments
11.3 Novavax
11.3.1 Novavax Corporation Information
11.3.2 Novavax Overview
11.3.3 Novavax Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Novavax Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novavax Recent Developments
11.4 Agenus
11.4.1 Agenus Corporation Information
11.4.2 Agenus Overview
11.4.3 Agenus Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Agenus Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Agenus Recent Developments
11.5 Croda International
11.5.1 Croda International Corporation Information
11.5.2 Croda International Overview
11.5.3 Croda International Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Croda International Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Croda International Recent Developments
11.6 Seppic
11.6.1 Seppic Corporation Information
11.6.2 Seppic Overview
11.6.3 Seppic Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Seppic Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Seppic Recent Developments
11.7 OZ Biosciences
11.7.1 OZ Biosciences Corporation Information
11.7.2 OZ Biosciences Overview
11.7.3 OZ Biosciences Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 OZ Biosciences Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 OZ Biosciences Recent Developments
11.8 Phibro Animal Health Corporation
11.8.1 Phibro Animal Health Corporation Corporation Information
11.8.2 Phibro Animal Health Corporation Overview
11.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Phibro Animal Health Corporation Recent Developments
11.9 Associated British Foods
11.9.1 Associated British Foods Corporation Information
11.9.2 Associated British Foods Overview
11.9.3 Associated British Foods Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Associated British Foods Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Associated British Foods Recent Developments
11.10 InvivoGen
11.10.1 InvivoGen Corporation Information
11.10.2 InvivoGen Overview
11.10.3 InvivoGen Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 InvivoGen Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 InvivoGen Recent Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Corporation Information
11.11.2 Merck KGaA Overview
11.11.3 Merck KGaA Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Merck KGaA Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Merck KGaA Recent Developments
11.12 CSL Limited
11.12.1 CSL Limited Corporation Information
11.12.2 CSL Limited Overview
11.12.3 CSL Limited Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 CSL Limited Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 CSL Limited Recent Developments
11.13 Vertellus
11.13.1 Vertellus Corporation Information
11.13.2 Vertellus Overview
11.13.3 Vertellus Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Vertellus Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Vertellus Recent Developments
11.14 Allergy Therapeutics
11.14.1 Allergy Therapeutics Corporation Information
11.14.2 Allergy Therapeutics Overview
11.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Allergy Therapeutics Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Allergy Therapeutics Recent Developments
11.15 Riboxx GmbH
11.15.1 Riboxx GmbH Corporation Information
11.15.2 Riboxx GmbH Overview
11.15.3 Riboxx GmbH Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Riboxx GmbH Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Riboxx GmbH Recent Developments
11.16 CaPtivatϵ Pharmaceuticals
11.16.1 CaPtivatϵ Pharmaceuticals Corporation Information
11.16.2 CaPtivatϵ Pharmaceuticals Overview
11.16.3 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 CaPtivatϵ Pharmaceuticals Recent Developments
11.17 EuBiologics
11.17.1 EuBiologics Corporation Information
11.17.2 EuBiologics Overview
11.17.3 EuBiologics Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 EuBiologics Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 EuBiologics Recent Developments
11.18 Pacific GeneTech
11.18.1 Pacific GeneTech Corporation Information
11.18.2 Pacific GeneTech Overview
11.18.3 Pacific GeneTech Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Pacific GeneTech Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Pacific GeneTech Recent Developments
11.19 Hawaii Biotech
11.19.1 Hawaii Biotech Corporation Information
11.19.2 Hawaii Biotech Overview
11.19.3 Hawaii Biotech Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Hawaii Biotech Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Hawaii Biotech Recent Developments
11.20 Vaxine Pty Ltd.
11.20.1 Vaxine Pty Ltd. Corporation Information
11.20.2 Vaxine Pty Ltd. Overview
11.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Vaxine Pty Ltd. Recent Developments
11.21 Creative Diagnostics
11.21.1 Creative Diagnostics Corporation Information
11.21.2 Creative Diagnostics Overview
11.21.3 Creative Diagnostics Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Creative Diagnostics Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Creative Diagnostics Recent Developments
11.22 LiteVax BV
11.22.1 LiteVax BV Corporation Information
11.22.2 LiteVax BV Overview
11.22.3 LiteVax BV Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 LiteVax BV Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 LiteVax BV Recent Developments
11.23 Mukta Industries
11.23.1 Mukta Industries Corporation Information
11.23.2 Mukta Industries Overview
11.23.3 Mukta Industries Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 Mukta Industries Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 Mukta Industries Recent Developments
11.24 Oncovir
11.24.1 Oncovir Corporation Information
11.24.2 Oncovir Overview
11.24.3 Oncovir Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 Oncovir Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 Oncovir Recent Developments
11.25 TiterMax USA
11.25.1 TiterMax USA Corporation Information
11.25.2 TiterMax USA Overview
11.25.3 TiterMax USA Biological Vaccines Adjuvants Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 TiterMax USA Biological Vaccines Adjuvants Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 TiterMax USA Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Biological Vaccines Adjuvants Industry Chain Analysis
12.2 Biological Vaccines Adjuvants Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biological Vaccines Adjuvants Production Mode & Process
12.4 Biological Vaccines Adjuvants Sales and Marketing
12.4.1 Biological Vaccines Adjuvants Sales Channels
12.4.2 Biological Vaccines Adjuvants Distributors
12.5 Biological Vaccines Adjuvants Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Biological Vaccines Adjuvants Industry Trends
13.2 Biological Vaccines Adjuvants Market Drivers
13.3 Biological Vaccines Adjuvants Market Challenges
13.4 Biological Vaccines Adjuvants Market Restraints
14 Key Findings in The Global Biological Vaccines Adjuvants Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer